Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on April 28, 2025
Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI …
Hudbay Signs Exploration Agreement with the Mosakahiken Cree Nation for the Talbot Deposit in Manitoba
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) today announced the signing of an agreement with the Mosakahiken Cree Nation (“MCN”) on exploration activities in their traditional and ancestral …
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
GlobeNewswire
·
April 28, 2025
Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancer NT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand …
Trust Wallet Launches ‘Stablecoin Earn’ to Boost Crypto Earning Opportunities*
GlobeNewswire
·
April 28, 2025
Users can earn seamlessly on stablecoins with flexible, secure onchain strategies — while maintaining full control over assets. DUBAI, United Arab Emirates, April 28, 2025 (GLOBE NEWSWIRE) -- Trust Wallet, the world’s leading self-custody Web3 wallet …
ImPact Biotech Presents Updated Efficacy Data from Evaluation of Padeliporfin VTP in LG UTUC and Intermediate-Risk Prostate Cancer at AUA 2025
GlobeNewswire
·
April 28, 2025
– Complete response (CR) observed in 79% (26/33) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) of the ENLIGHTED Phase 3 trial evaluating Padeliporfin VTP in UTUC – – Padeliporfin …
Quanta Therapeutics Presents Late-Breaking Data for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, at AACR Annual Meeting 2025
GlobeNewswire
·
April 28, 2025
- Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in combination with cetuximab in patients with KRASG12V mutations …
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.
GlobeNewswire
·
April 28, 2025
Acquisition of approximately 71% stake in Kokomodo Ltd. Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, …
Hudbay’s Eugene Lei wins Globe and Mail’s Report on Business 2025 Best Executive Award
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Hudbay Minerals Inc. (“Hudbay” or the “Company”) (TSX, NYSE: HBM) is pleased to announce that Eugene Lei, Chief Financial Officer at Hudbay, has been recognized as a winner of the Globe and Mail’s Report on …
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
·
April 28, 2025
WATERTOWN, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today …
Arvinas to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
GlobeNewswire
·
April 28, 2025
NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first …
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 28, 2025
BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter …
XORTX Announces Grant of European Patent
GlobeNewswire
·
April 28, 2025
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Nayax to Showcase End-to-End Payment Ecosystem at The NAMA Show, May 7-9 in Las Vegas
GlobeNewswire
·
April 28, 2025
HERZLIYA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement payments and loyalty platform designed to help merchants scale their business, will be showcasing its range of solutions at The NAMA …
Azimut met en place un investissement stratégique par Centerra Gold
GlobeNewswire
·
April 28, 2025
LONGUEUIL, Québec, 28 avr. 2025 (GLOBE NEWSWIRE) -- Exploration Azimut Inc. (« Azimut » ou la « Société ») (TSXV : AZM; OTCQX : AZMTF) annonce que la Société a conclu une convention de souscription avec Centerra Gold Inc. (“Centerra”) (TSX: CG) (NYSE: CGAU …
Allot to Release First Quarter 2025 Results and Host Conference Call on May 12, 2025
GlobeNewswire
·
April 28, 2025
Hod Hasharon, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Allot Ltd. (NASDAQ: ALLT, TASE: ALLT), a leading global provider of innovative security-as-a-service (SECaaS) and network intelligence solutions for communication service providers (CSPs) and …
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025
GlobeNewswire
·
April 28, 2025
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025 Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class therapies for gut health, …